New Age Alpha Advisors LLC Reduces Position in Zoetis Inc. $ZTS

New Age Alpha Advisors LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 10.6% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 45,520 shares of the company’s stock after selling 5,370 shares during the quarter. New Age Alpha Advisors LLC’s holdings in Zoetis were worth $6,660,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently modified their holdings of the business. Vanguard Group Inc. grew its stake in Zoetis by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock valued at $6,190,326,000 after buying an additional 419,777 shares in the last quarter. Geode Capital Management LLC boosted its holdings in shares of Zoetis by 0.9% in the second quarter. Geode Capital Management LLC now owns 11,081,301 shares of the company’s stock worth $1,721,356,000 after acquiring an additional 95,294 shares during the period. Norges Bank purchased a new position in shares of Zoetis in the second quarter valued at $809,491,000. Brown Advisory Inc. grew its position in shares of Zoetis by 5.7% in the second quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock valued at $726,629,000 after purchasing an additional 250,829 shares in the last quarter. Finally, Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in shares of Zoetis by 14.6% during the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock valued at $631,046,000 after purchasing an additional 550,859 shares during the period. Institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $131.06 on Friday. Zoetis Inc. has a 52-week low of $115.25 and a 52-week high of $177.00. The company has a fifty day moving average of $126.05 and a 200-day moving average of $134.05. The company has a market capitalization of $55.32 billion, a P/E ratio of 21.77, a P/E/G ratio of 2.00 and a beta of 0.96. The company has a debt-to-equity ratio of 2.71, a quick ratio of 1.94 and a current ratio of 3.03.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The business had revenue of $2.39 billion for the quarter, compared to the consensus estimate of $2.36 billion. During the same quarter last year, the business posted $1.40 earnings per share. The company’s revenue for the quarter was up 3.0% on a year-over-year basis. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, equities research analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 1.6%. The ex-dividend date is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Analyst Ratings Changes

Several research analysts have commented on ZTS shares. JPMorgan Chase & Co. cut their target price on Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research note on Wednesday, November 5th. BTIG Research reissued a “buy” rating and issued a $160.00 price target on shares of Zoetis in a report on Thursday. Stifel Nicolaus reduced their price objective on shares of Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. KeyCorp initiated coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating on the stock. Finally, HSBC set a $140.00 price target on shares of Zoetis in a report on Wednesday, December 10th. Five analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $152.91.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.